- Previous Close
0.0000 - Open
-- - Bid --
- Ask --
- Day's Range
-- - 52 Week Range
1.2400 - 16.0000 - Volume
-- - Avg. Volume
0 - Market Cap (intraday)
-- - Beta (5Y Monthly) 3.26
- PE Ratio (TTM)
-- - EPS (TTM)
-2.5900 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. The company's lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat COVID-19 virus, as well as to treat brain cancers and/or certain neurodegenerative diseases; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and cell therapy products for bone marrow/hematopoietic stem cell transplantation. Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.
hemogenyx.comRecent News: HOPHD
View MorePerformance Overview: HOPHD
Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HOPHD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HOPHD
View MoreValuation Measures
Market Cap
16.92M
Enterprise Value
18.32M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.05
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-37.79%
Return on Equity (ttm)
-155.97%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-5.18M
Diluted EPS (ttm)
-2.5900
Balance Sheet and Cash Flow
Total Cash (mrq)
1.64M
Total Debt/Equity (mrq)
92.09%
Levered Free Cash Flow (ttm)
-2.73M